Key Takeaways
- Domestic formulation holds, exports surge: Domestic business grew ~10% in a tough quarter, while export generics jumped ~32%, prompting a sharp guidance upgrade for the year.
- Unichem integration is the central story: Consolidated from August 1, Unichem contributed ₹285 Cr topline but posted a ₹16 Cr bottom-line loss; management targets ₹300 Cr EBITDA in about two years.
- US re-entry is a Q1 FY25 event: With import alerts lifted on two plants and a third expected shortly, supply chain revalidation puts the earliest US shipments in Q1 of next financial year.
- API business remains a drag: Severe price erosion, exemplified by Losartan dropping from $100 to $50, continues to pressure the segment despite stable volumes.
- What to watch next quarter: The pace of Unichem’s cost-synergy execution, the actual lifting of the Pithampur import alert, and whether the upgraded export generic guidance holds.
Unichem Integration & Turnaround
- Consolidation started: Unichem was consolidated line-by-line from August 1, 2023, contributing a topline of around ₹285 Crores, a bottom-line loss of around ₹16 Crores, and a positive EBITDA of around 5% for the period.
- Cost synergy offensive: Short-term initiatives target raw material cost reduction of 15% to 40% on certain products via API process changes, 30% to 40% API cost reductions on some processes, and utility cost savings of around ₹12-14 Crores expected in the current financial year. Procurement alignment and logistic cost reduction, where over 50% of shipments were by air, are also underway.
- Market extension unlocks value: 24 ANDA products can gain market extension in around 18 months with minor dossier tweaking, though regulatory approvals will add time. US ANDA approvals can be leveraged for the Chile market without backward work.
- Product pipeline is loaded: 11 new products are launchable in 2023-2024, with nine ANDAs from April 2024 to March 2025 and seven ANDAs including three Para IVs in 2024 or 2025.
- API integration is a 12-15 month goal: 10-12 common APIs where IPCA’s production costs are lower can be integrated into Unichem’s basket, a process targeted for around 12 to 15 months.
- R&D is pivoting to process fixes: For the next two years, almost 80% of R&D time will be devoted to improvements and process corrections, with only 20% on new developments, until major API corrections are complete.
- Goa 2 plant is vastly underutilized: Current production volume is around 5 crore tablets out of a 50 crore tablet capacity. Shifting larger volume products there after regulatory approval may take around one year, freeing up capacity and reducing costs.
- No merger planned: Both IPCA and Unichem will remain separately listed entities with no current plans for a share swap; US marketing will run through a combined Unichem and Bay Shore outfit to reduce operating costs.
A. K. Jain: "we are very confident that what we had talked initially when we have announced the deal that we will be able to achieve almost around Rs.300 Crores kind of EBITDA on the Unichem side that is very much possible looking into all these details what we have done and once the market extension happens and we start marketing those products in various market definitely we can make Unichem as a beautiful company."
US Market Re-entry
- Regulatory path clearing: Import alerts have already been lifted for the Piparia and Ratlam plants; the Pithampur plant, already classified as VAI, is awaiting a lift expected shortly. Both formulations plants and the Ratlam API plant are now in the VAI category.
- Shipments begin Q1 FY25: The process of augmenting the supply chain and revalidating all formulations has been initiated and may take around four to five months, putting the earliest US shipments in Q1 of the next financial year.
- Margin structure improves: Previously, IPCA shared almost 40% to 50% of profit with a marketing partner. Now all products will be distributed through the Unichem franchise, eliminating that profit share and improving margins.
- Pricing has held: In IPCA’s product range, there has been hardly any reduction in prices in the US market since the company exited, preserving the value of the returning portfolio.
- Recovery will be gradual: Management cautioned that nobody is waiting for IPCA and the company will have to create the market, so regaining lost business will take time. The historical US business, including indirect API sales, was about ₹500 crores with 9 to 10 formulations being marketed.
- Filing strategy is API-led: Filings will be based on IPCA’s own API; wherever the company has good API processes, those molecules will be taken for filing, making the US business more integrated.
Harish Kamath: "as far as the pricing is concerned in our product range there is hardly any reduction in the prices in that market so when we were there we were sharing almost 40% to 50% profit with the marketing partner. Now that issue is not there."
Domestic Formulation & Branded Markets
- Outpaced the market in a tough quarter: Q2 was the toughest quarter with overall market growth around 7%; IPCA grew around 10%, outpacing the industry in both acute and chronic segments. H1 growth was around 12%.
- Therapy-level growth was broad: Pain grew 12%, cardiac 13%, CNS 22%, derma 17%, neurology 23%, and ophthalmology 38%. Anti-malarial declined 4%, anti-bacterial 2%, and cough and cold 5%.
- MR productivity is rising: Overall MR productivity improved to around ₹4,53,000 per month from ₹4,18,000 last year. The FTA division delivered productivity of almost ₹9,30,000, while the rheumatoid arthritis segment reached around ₹4 lakh. The cardiology division, after one year, is at around ₹1 lakh productivity.
- Full-year guidance maintained at 12-14%: Despite Q2 being around 10%, management maintained the domestic growth guidance of around 12% to 14% for the year, citing a good October and November.
- International branded business lowered: Growth projection was reduced to around 12% due to depreciation in the Russian Ruble and contingent challenges in West Africa, though H1 delivered around 18%.
Export Generics & API
- Export generics surge drives guidance upgrade: Export generics delivered around 32% growth in Q2, mainly from UK and European markets. Full-year guidance was revised sharply upward to around 20% growth from an initial projection of 7% to 8%, with H1 already delivering around 21%.
- South Africa tender loss offset: The earlier expected loss of around ₹60 Crores from lost tenders in South Africa may not materialize as private market and other businesses have performed well.
- API business under price pressure: The API segment continued to face both price and volume declines, with severe price erosion on certain products. Losartan dropped from $100 to about $50, though volume decline was less pronounced.
- API seeding is progressing: Across all products, seeding across the globe has shown good business progress and many projects are now getting commercialized. Management stated the only issue is pricing, with no other concerns.
- Capacity utilization is low but scaling: Piparia is at 15% to 20%, Pithampur around 30%, while the Devas plant is gradually scaling up with around six to seven APIs stood up and filings in process. Ratlam has specific capacity available for specific products.
- Continuous process plant near launch: A plant for one intermediate has been installed at Aurangabad and commercial production may start end-December. Additional continuous process plants are planned at Nagpur, where environmental clearance has been received but consent to start is pending from the state pollution control board.
Biosimilars & R&D
- Biosimilar plant under construction: The biosimilar plant is expected to complete by the end of Q1 next year. After completion, it may take around two and a half years for initial batches, establishment batches, bio development, and clinical studies before commercialization.
- Pipeline of five products advancing: IPCA is currently working on around five biosimilar products. For two, IMA, USFDA and European authority guidelines and clinical strategies have been finalized; a third is in the pipeline. Target markets are Europe and the US.
- R&D spend set to rise: R&D cost is currently around 2.5% of revenue and will increase to maybe up to 4% as IPCA increases its filing pace going forward. As a group, IPCA will have a significant number of ANDAs in the US.
A. K. Jain: "Looking at our R&D presentations and all we are getting values are much higher than currently what market is getting. That is what I can say but I cannot give the name of the production right now."
Margin & Profitability Outlook
- EBITDA margin improvement pledged: Management expressed confidence that EBITDA margin should improve at least 100 basis points year after year going forward, driven by operating leverage and cost initiatives.
- Unichem drag to fade: The Unichem business posted a bottom-line loss of around ₹16 Crores in the partial quarter, but Ireland and UK losses are expected to reduce and may result in profitability in the current year. The first goal is to turn Unichem into profitability, with low-hanging fruits addressed immediately and longer initiatives taking 12-18 months.
- Unichem Brazil turning around: The Brazil business, which was earlier cash burning, has started doing well and grew almost 65% in the first half. A good pipeline of products and the Sartan journey integration support a positive outlook for Brazil and European business.
Harish Kamath: "we are confident of telling and assuring the investors our EBITDA margin going forward should improve at least by 100 basis points year after year."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Domestic formulation growth | 12% to 14% growth for the full year | FY24 |
| Export generic growth | Around 20% growth (revised from 7-8%) | FY24 |
| International branded business growth | Around 12% growth (lowered) | FY24 |
| US market re-entry | First shipments to US begin | Q1 FY25 |
| Unichem EBITDA target | Around ₹300 Crores EBITDA | About two years |
| Unichem profitability | Ireland and UK markets to show no losses, possibly profitable | Current year (FY24) |
| Unichem product launches | 11 new products launchable | FY24 |
| Unichem ANDA launches | Nine ANDAs | April 2024 to March 2025 |
| Unichem ANDA launches (incl. Para IV) | Seven ANDAs including three Para IV | 2024 or 2025 |
| Unichem API integration | 10-12 common APIs integrated into Unichem basket | 12 to 15 months |
| Unichem market extension | 24 ANDA products extended to new markets | Around 18 months (plus regulatory time) |
| R&D cost increase | From ~2.5% to up to 4% of revenue | Going forward (no end date) |
| EBITDA margin improvement | At least 100 bps improvement year after year | Ongoing |
| Biosimilar plant completion | Plant construction complete | End of Q1 next year |
| Continuous process plant (Aurangabad) | Commercial production start | End-December |
| Devas plant Europe inspection | Regulatory inspection | Year-end or early next year |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Domestic formulation growth | ~10% YoY, with two range jump over corresponding period |
| Market share (MAT basis) | 1.92%, improved from 1.89% as of mid-September 2023 per IQVIA |
| Branded promotional business revenue | ~₹146 cr, +15% YoY from ₹127 cr |
| Export generic business revenue | ~₹264 cr, +32% YoY from ₹200 cr |
| Institutional tender anti-malarial revenue | ~₹61 cr, -21% YoY from ₹77 cr |
| Overall export formulation revenue | ~₹470 cr, +16% YoY from ₹404 cr |
| API business revenue | ~₹335 cr, +6% YoY from ₹307 cr |
| Unichem consolidated topline (2 months) | ~₹285 cr, consolidated from August 1, 2023 |
| Unichem consolidated bottom line (2 months) | Loss of ~₹16 cr |
| Unichem EBITDA margin (2 months) | ~5%, positive |
| Standalone EBITDA margin | 20.86%, improved from 18.85% in Q2 FY23 |
| Consolidated EBITDA margin | 17.64%, improved from 17% in Q2 FY23 despite two months of Unichem |
| Effective tax rate (IPCA standalone) | ~34%, including deferred tax, vs normal rate of ~25% plus 1-2% deferred tax |
| Net borrowing | ~₹800 cr, cost around 7%; gross borrowing ~₹1,600 cr with ~₹800 cr cash |
| MR productivity (monthly) | ~₹4,53,000, up from ₹4,18,000 last year |